Cargando…

Fractalkine (CX3CL1), a new factor protecting β-cells against TNFα

OBJECTIVE: We have previously shown the existence of a muscle–pancreas intercommunication axis in which CX3CL1 (fractalkine), a CX3C chemokine produced by skeletal muscle cells, could be implicated. It has recently been shown that the fractalkine system modulates murine β-cell function. However, the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rutti, Sabine, Arous, Caroline, Schvartz, Domitille, Timper, Katharina, Sanchez, Jean-Charles, Dermitzakis, Emmanouil, Donath, Marc Y., Halban, Philippe A., Bouzakri, Karim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209359/ https://www.ncbi.nlm.nih.gov/pubmed/25353001 http://dx.doi.org/10.1016/j.molmet.2014.07.007

Ejemplares similares

IL-13 improves beta-cell survival and protects against IL-1beta-induced beta-cell death
por: Rütti, Sabine, et al.
Publicado: (2015)

In Vitro Proliferation of Adult Human Beta-Cells
por: Rutti, Sabine, et al.
Publicado: (2012)

Fractalkine/CX3CL1 in Neoplastic Processes
por: Korbecki, Jan, et al.
Publicado: (2020)

EHMTI-0062. Expression of fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) in the trigeminal ganglia: implications for craniofacial nociception
por: Gazerani, P, et al.
Publicado: (2014)

CX3CL1 (fractalkine) and TNFα production by perfused human placental lobules under normoxic and hypoxic conditions in vitro: the importance of CX3CR1 signaling
por: Szukiewicz, Dariusz, et al.
Publicado: (2013)

The Chemokine CX3CL1 (Fractalkine) and its Receptor CX3CR1: Occurrence and Potential Role in Osteoarthritis
por: Wojdasiewicz, Piotr, et al.
Publicado: (2014)

Therapeutic intervention of inflammatory/immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway
por: Imai, Toshio, et al.
Publicado: (2016)

Fractalkine Signalling (CX(3)CL1/CX(3)CR1 Axis) as an Emerging Target in Coronary Artery Disease
por: Loh, Shu Xian, et al.
Publicado: (2023)

Angiogenin and Osteoprotegerin are type II muscle specific myokines protecting pancreatic beta-cells against proinflammatory cytokines
por: Rutti, Sabine, et al.
Publicado: (2018)

Fractalkine (CX3CL1) and Its Receptor CX3CR1 May Contribute to Increased Angiogenesis in Diabetic Placenta
por: Szukiewicz, Dariusz, et al.
Publicado: (2013)

CX3CL1 (Fractalkine) Protein Expression in Normal and Degenerating Mouse Retina: In Vivo Studies
por: Zieger, Marina, et al.
Publicado: (2014)

Rhinovirus induction of fractalkine (CX3CL1) in airway and peripheral blood mononuclear cells in asthma
por: Upton, Nadine, et al.
Publicado: (2017)

Comparative Analysis of the Occurrence and Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Hemophilic Arthropathy and Osteoarthritis
por: Wojdasiewicz, Piotr, et al.
Publicado: (2020)

Fractalkine (CX3CL1) and Its Receptor CX3CR1: A Promising Therapeutic Target in Chronic Kidney Disease?
por: Cormican, Sarah, et al.
Publicado: (2021)

Pathological Role of Fractalkine/CX3CL1 in Rheumatic Diseases: A Unique Chemokine with Multiple Functions
por: Jones, Brian, et al.
Publicado: (2012)

CX3CL1/fractalkine shedding by human hepatic stellate cells: contribution to chronic inflammation in the liver
por: Bourd-Boittin, Katia, et al.
Publicado: (2009)

Fractalkine (CX3CL1), GM-CSF and VEGF-a levels are reduced by statins in adult patients
por: Cimato, Thomas R, et al.
Publicado: (2014)

Fractalkine/CX3CL1 engages different neuroprotective responses upon selective glutamate receptor overactivation
por: Lauro, Clotilde, et al.
Publicado: (2015)

CX3CL1/fractalkine enhances prostate cancer spinal metastasis by activating the Src/FAK pathway
por: Liu, Peng, et al.
Publicado: (2018)

Bimodal Effect on Pancreatic β-Cells of Secretory Products From Normal or Insulin-Resistant Human Skeletal Muscle
por: Bouzakri, Karim, et al.
Publicado: (2011)

Elevated Expression of Fractalkine (CX3CL1) and Fractalkine Receptor (CX3CR1) in the Dorsal Root Ganglia and Spinal Cord in Experimental Autoimmune Encephalomyelitis: Implications in Multiple Sclerosis-Induced Neuropathic Pain
por: Zhu, Wenjun, et al.
Publicado: (2013)

Corrigendum to “Comparative Analysis of the Occurrence and Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Hemophilic Arthropathy and Osteoarthritis”
por: Wojdasiewicz, Piotr, et al.
Publicado: (2020)

Neuronal autophagy aggravates microglial inflammatory injury by downregulating CX3CL1/fractalkine after ischemic stroke
por: He, Hong-Yun, et al.
Publicado: (2019)

The chemokine fractalkine (CX3CL1) attenuates H(2)O(2)-induced demyelination in cerebellar slices
por: O’Sullivan, Sinead A., et al.
Publicado: (2017)

CX(3)CL1 (fractalkine) and CX(3)CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin
por: Sunnemark, Dan, et al.
Publicado: (2005)

CX(3)CL1 (fractalkine) and its receptor CX(3)CR1 regulate atopic dermatitis by controlling effector T cell retention in inflamed skin
por: Staumont-Sallé, Delphine, et al.
Publicado: (2014)

Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient
por: Siddiqui, Imran, et al.
Publicado: (2016)

Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity
por: Suzuki, Fumihito, et al.
Publicado: (2012)

Role of Fractalkine/CX3CL1 and Its Receptor in the Pathogenesis of Inflammatory and Malignant Diseases with Emphasis on B Cell Malignancies
por: Ferretti, Elisa, et al.
Publicado: (2014)

Increased circulatory levels of fractalkine (CX3CL1) are associated with inflammatory chemokines and cytokines in individuals with type-2 diabetes
por: Sindhu, Sardar, et al.
Publicado: (2017)

Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients
por: Marchica, Valentina, et al.
Publicado: (2019)

Cathepsin S activation contributes to elevated CX3CL1 (fractalkine) levels in tears of a Sjögren’s syndrome murine model
por: Fu, Runzhong, et al.
Publicado: (2020)

Fractalkine/CX3CR1 signaling during neuropathic pain
por: Clark, Anna K., et al.
Publicado: (2014)

Fractalkine/CX(3)CR(1) Pathway in Neuropathic Pain: An Update
por: Silva, Rita, et al.
Publicado: (2021)

Early expression of the fractalkine receptor CX3CR1 in pancreatic carcinogenesis
por: Celesti, G, et al.
Publicado: (2013)

Fractalkine/CX(3)CL1 protects striatal neurons from synergistic morphine and HIV-1 Tat-induced dendritic losses and death
por: Suzuki, Masami, et al.
Publicado: (2011)

Type I interferon induces CX3CL1 (fractalkine) and CCL5 (RANTES) production in human pulmonary vascular endothelial cells
por: Nakano, M, et al.
Publicado: (2012)

MicroRNA-424 regulates the expression of CX3CL1 (fractalkine) in human microvascular endothelial cells during Rickettsia rickettsii infection
por: Sahni, Abha, et al.
Publicado: (2021)

Association of CX3CR1 Gene Polymorphisms with Fractalkine, Fractalkine Receptor, and C-Reactive Protein Levels in Patients with Kidney Failure
por: Woźny, Łukasz, et al.
Publicado: (2021)

Analysis of the Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Traumatic Brain and Spinal Cord Injury: Insight into Recent Advances in Actions of Neurochemokine Agents
por: Poniatowski, Łukasz A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cg58p4qpnoqml5c6bn3b5tlk72